JP2024509280A5 - - Google Patents
Info
- Publication number
- JP2024509280A5 JP2024509280A5 JP2023555330A JP2023555330A JP2024509280A5 JP 2024509280 A5 JP2024509280 A5 JP 2024509280A5 JP 2023555330 A JP2023555330 A JP 2023555330A JP 2023555330 A JP2023555330 A JP 2023555330A JP 2024509280 A5 JP2024509280 A5 JP 2024509280A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- disease
- disorder
- medical condition
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163159024P | 2021-03-10 | 2021-03-10 | |
| US63/159,024 | 2021-03-10 | ||
| PCT/US2022/019449 WO2022192332A1 (en) | 2021-03-10 | 2022-03-09 | Pyridopyrimidine derivatives as kras inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024509280A JP2024509280A (ja) | 2024-02-29 |
| JP2024509280A5 true JP2024509280A5 (enExample) | 2025-03-17 |
Family
ID=83228274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023555330A Pending JP2024509280A (ja) | 2021-03-10 | 2022-03-09 | Ｋｒａｓ阻害物質としてのピリドピリミジン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240140948A1 (enExample) |
| EP (1) | EP4281457A4 (enExample) |
| JP (1) | JP2024509280A (enExample) |
| CN (1) | CN116964057A (enExample) |
| AU (1) | AU2022234388A1 (enExample) |
| WO (1) | WO2022192332A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250276968A1 (en) * | 2022-05-09 | 2025-09-04 | Beta Pharma, Inc. | 8- and 6-substituted pyridopyrimidine derivatives as kras inhibitors |
| AU2023356610A1 (en) * | 2022-10-05 | 2025-04-03 | Amgen Inc. | Tethered heterocyclic inhibitors of kras g12c mutant proteins and uses thereof |
| US20260216179A1 (en) * | 2022-10-31 | 2026-07-30 | Beta Pharma, Inc. | 1,5-naphthyridine derivatives as kras oncoprotein inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2863873T3 (es) * | 2016-05-18 | 2021-10-11 | Mirati Therapeutics Inc | Inhibidores de KRAS G12C |
| JP2019529484A (ja) * | 2016-09-29 | 2019-10-17 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤 |
| UA127968C2 (uk) * | 2017-05-22 | 2024-02-28 | Емджен Інк. | Інгібітори g12c kras і способи їх застосування |
| ES2961253T3 (es) * | 2018-08-31 | 2024-03-11 | Mirati Therapeutics Inc | Inhibidores de KRas G12C |
| WO2020146613A1 (en) * | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| CN114615981B (zh) * | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| WO2022135470A1 (zh) * | 2020-12-22 | 2022-06-30 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| CN113999226B (zh) * | 2020-12-22 | 2023-01-06 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| US20250276968A1 (en) * | 2022-05-09 | 2025-09-04 | Beta Pharma, Inc. | 8- and 6-substituted pyridopyrimidine derivatives as kras inhibitors |
-
2022
- 2022-03-09 CN CN202280020555.5A patent/CN116964057A/zh active Pending
- 2022-03-09 AU AU2022234388A patent/AU2022234388A1/en not_active Abandoned
- 2022-03-09 US US18/547,052 patent/US20240140948A1/en not_active Abandoned
- 2022-03-09 JP JP2023555330A patent/JP2024509280A/ja active Pending
- 2022-03-09 EP EP22767851.3A patent/EP4281457A4/en not_active Withdrawn
- 2022-03-09 WO PCT/US2022/019449 patent/WO2022192332A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023515479A5 (enExample) | ||
| JP2020007311A5 (enExample) | ||
| JP2024516997A5 (enExample) | ||
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2022520061A5 (enExample) | ||
| JP2022505835A5 (enExample) | ||
| JP2015536994A5 (enExample) | ||
| JP2009515992A5 (enExample) | ||
| JP2010528021A5 (enExample) | ||
| JP2019510798A5 (enExample) | ||
| RU2012144751A (ru) | Гетероциклические соединения, эффективные для ингибирования киназы | |
| RU2015143542A (ru) | Ингибиторы jak2 и alk2 и способы их использования | |
| JP2008528467A5 (enExample) | ||
| JP2016509056A5 (enExample) | ||
| JP2008535902A5 (enExample) | ||
| JP2008527038A5 (enExample) | ||
| JP2009541223A5 (enExample) | ||
| WO2016161361A4 (en) | Compositions and methods of targeting mutant k-ras | |
| JP2009514881A5 (enExample) | ||
| JP2011511095A5 (enExample) | ||
| JP2015533177A5 (enExample) | ||
| JP2010526097A5 (enExample) | ||
| JP2016503414A5 (enExample) | ||
| RU2013150102A (ru) | Ингибиторы parp для лечения cipn | |
| JP2010519174A5 (enExample) |